[ORGANIZATION]
Remibrutinib
Featured in 5 tracked stories · first seen
Situations
Novartis remibrutinib clinical development
2 clusters · 11 sources · last updated
Latest: Novartis remibrutinib reduces multiple sclerosis relapse rates
Novartis is advancing the clinical application of remibrutinib, an oral Bruton tyrosine kinase (BTK) inhibitor, across different medical indications. In October 2026, the US Food and Drug Administration (FDA) approved r
Also covered in
-
Yuhan Corporation and Novartis Korea partner to distribute Remibrutinib
[BUSINESS] · 2 sources ·